Mirae Asset Global ETFs Holdings

Mirae Asset Global ETFs Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06M	Buy	88,484 +4	+0%	+$102	﹤0.01%	1157
2025 Q4	$2.56M	Sell	88,480 -7,145	-7%	-$183K	﹤0.01%	1044
2025 Q3	$1.8M	Buy	95,625 +29,389	+44%	+$463K	﹤0.01%	1186
2025 Q2	$927K	Sell	66,236 -5,181	-7%	-$72.6K	﹤0.01%	1481
2025 Q1	$1.12M	Buy	71,417 +2,063	+3%	+$29.1K	﹤0.01%	1446
2024 Q4	$968K	Sell	69,354 -15	-0%	-$164	﹤0.01%	1561
2024 Q3	$646K	Buy	69,369 +18,925	+38%	+$187K	﹤0.01%	1789
2024 Q2	$470K	Buy	+50,444	New	+$456K	﹤0.01%	1855

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return